ReviewJournal of cancer research and clinical oncology2016
The role of stress and beta-adrenergic system in melanoma: current knowledge and possible therapeutic options.
Review in Journal of cancer research and clinical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- β-Blocker use is not associated with improved clinical outcomes in women with breast cancer: a meta-analysis.Bioscience reports · 2020Pooled it
- Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023Article
- Review: The Key Factors to Melanomagenesis.Life (Basel, Switzerland) · 2023Review
- Review
- Neuroendocrine Factors in Melanoma Pathogenesis.Cancers · 2021Review
- Anxiety and depression after diagnosis of high-risk primary cutaneous melanoma: a 4-year longitudinal study.Journal of cancer survivorship : research and practice · 2020Article
- Current Therapies and New Targets to Fight Melanoma: A Promising Role for the β3-Adrenoreceptor.Cancers · 2020Review
- Effect of β-Blocker in Treatment-Naïve Patients With Advanced Lung Adenocarcinoma Receiving First-Generation EGFR-TKIs.Frontiers in oncology · 2020Article
- Effect of lidocaine on the safety of postoperative skin reconstruction after malignant melanoma resection.Experimental and therapeutic medicine · 2019Article
- Exploring Knowledge, Attitudes, and Practice Associated With Meditation Among Patients With Melanoma.Integrative cancer therapies · 2018Article
- β-Adrenergic modulation of cancer cell proliferation: available evidence and clinical perspectives.Journal of cancer research and clinical oncology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of the present review was to discuss recent findings on the role of beta-adrenergic system in melanoma, in order to provide information on the biological responses elicited by its activation and its potential application for melanoma treatment.
methodsA literature search was performed, and evidences regarding the involvement of stress and beta-adrenergic system in cancer and melanoma were found and discussed.
resultsOur search pointed out that beta-adrenergic system is a key regulator of important biological processes involved in the onset and progression of some solid tumors. In the last decade, functional beta-adrenoceptors have been also identified on melanoma cells, as well as on their microenvironment cells. Similarly to other common cancers too, the activation of such adrenoceptors by catecholamines, usually released under stress conditions, has been found to trigger pro-tumorigenic pathways contributing to cell proliferation and motility, immune system regulation, apoptosis, epithelial-mesenchymal transition, invasion and neoangiogenesis.
conclusionsThe biological evidences we found clarify and sustain the clinical evidences reporting the involvement of chronic stress in melanoma onset and progression. In such scenario, it is conceivable that a therapeutic approach targeting beta-adrenergic system could constitute a novel and promising strategy for melanoma treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.